Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY trial of tyrosine kinase inhibitor de-escalation and stopping in chronic myeloid leukemia
2012-004025-24Phase 2Completed
- Sponsor
- University of Liverpool
- Start
- Jun 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of imatinib, dasatinib and nilotinib in chronic myelogenous leukemia (CML) (2 cohorts), sponsored by University of Liverpool. Primary endpoint: Loss of major molecular response. Started Jun 2013; status: completed.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2012-004025-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004025-24.